{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T01:04:20Z","timestamp":1789434260252,"version":"build-2803163510"},"reference-count":46,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Glucagon\u2010like peptide\u20101 receptor agonists (GLP\u20101RAs) and dual GIP\/GLP\u20101 receptor agonists are increasingly used for adolescent obesity, but concerns persist regarding psychiatric adverse events, particularly suicidality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cohort study used deidentified electronic health records from the TriNetX Global Collaborative Network. Adolescents with overweight or obesity were included. New users of semaglutide, liraglutide, or tirzepatide were compared with those receiving lifestyle interventions. Cohorts were balanced using propensity score matching. The primary outcome was suicide\u2010related events (suicidal ideation or suicide attempt). Secondary outcomes included suicidal ideation, suicide attempt, anxiety, insomnia, depression, and eating disorders, assessed from 30\u2009days to 1095\u2009days after the index date.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After propensity score matching, 9222 adolescents were included in each group. Incretin\u2010based therapy was associated with lower risks of suicide\u2010related events (HR, 0.74; 95% CI, 0.57\u20130.95), suicidal ideation (HR, 0.73; 95% CI, 0.56\u20130.96), and anxiety (HR, 0.92; 95% CI, 0.84\u20130.99) compared with lifestyle intervention. No significant differences were observed for suicide attempt, insomnia, depression, or eating disorders. Risk reductions were significant among female adolescents (HR, 0.61; 95% CI, 0.46\u20130.82) and those without Type 2 diabetes (HR, 0.63; 95% CI, 0.47\u20130.85), but not among males or those with Type 2 diabetes. Sensitivity analyses supported the primary findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Among adolescents with obesity, incretin\u2010based therapy was not associated with increased psychiatric risk and was associated with lower risks of suicide\u2010related events, suicidal ideation, and anxiety compared with lifestyle intervention. Although a lower risk was observed compared with lifestyle intervention, this finding should be interpreted cautiously given potential selection bias and the lack of a significant difference in the active\u2010comparator analysis with metformin.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.71353","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T01:00:03Z","timestamp":1789434003000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Psychiatric Safety of\n                    <scp>GLP<\/scp>\n                    \u20101 and Dual\n                    <scp>GIP<\/scp>\n                    \/\n                    <scp>GLP<\/scp>\n                    \u20101 Receptor Agonists in Adolescents With Obesity"],"prefix":"10.1111","author":[{"given":"Ting\u2010Hui","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Psychiatry Chi Mei Medical Center  Tainan Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang\u2010Li","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Psychiatry Chi Mei Hospital, Liouying  Tainan Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tien\u2010Hsiang","family":"Kuo","sequence":"additional","affiliation":[{"name":"School of Medicine Kaohsiung Medical University  Kaohsiung Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3290-1909","authenticated-orcid":false,"given":"Jheng\u2010Yan","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Nutrition Chi Mei Medical Center  Tainan Taiwan"},{"name":"Department of Public Health, College of Medicine National Cheng Kung University  Tainan Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien\u2010Ho","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Psychiatry Chi Mei Medical Center  Tainan Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6334-2388","authenticated-orcid":false,"given":"Chih\u2010Cheng","family":"Lai","sequence":"additional","affiliation":[{"name":"Department of Intensive Care Medicine Chi Mei Medical Center  Tainan Taiwan"},{"name":"School of Medicine, College of Medicine National Sun Yat\u2010Sen University  Kaohsiung Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,14]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"WHO \u201cWorld Health Statistics 2022 \u201d(2022)."},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2024.0921"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild\u20102017\u2010314608"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00787\u2010023\u201002191\u2010y"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.11809"},{"issue":"10511","key":"e_1_2_9_7_1","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1016\/S0140-6736(25)01774-X","article-title":"Efficacy and Safety of Tirzepatide in Children and Adolescents With Type 2 Diabetes (SURPASS\u2010PEDS): A Randomised, Double\u2010Blind, Placebo\u2010Controlled, Phase 3 Trial","volume":"406","author":"Hannon T. S.","year":"2025","journal-title":"Lancet"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2026.121802"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2024.10.062"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2024.4346"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1192\/j.eurpsy.2024.1803"},{"issue":"1","key":"e_1_2_9_12_1","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1080\/14740338.2023.2295397","article-title":"The Association Between Glucagon\u2010Like Peptide\u20101 Receptor Agonists (GLP\u20101 RAs) and Suicidality: Reports to the Food and Drug Administration Adverse Event Reporting System (FAERS)","volume":"23","author":"McIntyre R. S.","year":"2024","journal-title":"Expert Opinion on Drug Safety"},{"key":"e_1_2_9_13_1","unstructured":"European Medicines Agency \u201cEMA Statement on Ongoing Review of GLP\u20101 Receptor Agonists \u201d(2023)."},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2025.0679"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/s2213\u20108587(23)00388\u20101"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14020"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/oby.22726"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2025.3243"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2024.3812"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.13480"},{"issue":"4","key":"e_1_2_9_21_1","doi-asserted-by":"crossref","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity Analysis in Observational Research: Introducing the E Value","volume":"167","author":"VanderWeele T. J.","year":"2017","journal-title":"Annals of Internal Medicine"},{"key":"e_1_2_9_22_1","unstructured":"CDC \u201cChild and Teen BMI Categories \u201d(2024)."},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010023\u201002672\u20102"},{"key":"e_1_2_9_24_1","unstructured":"US Food and Drug Administration \u201cUpdate on FDA's Ongoing Evaluation of Reports of Suicidal Thoughts or Actions in Patients Taking a Certain Type of Medicines Approved for Type 2 Diabetes and Obesity \u201d(2026)."},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2024.4369"},{"key":"e_1_2_9_26_1","unstructured":"\u201cFDA Requests Removal of Suicidal Behavior and Ideation Warning From Glucagon\u2010Like Peptide\u20101 Receptor Agonist (GLP\u20101 RA) Medications \u201d(2026)."},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.70927"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.70175"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/cph4.70129"},{"issue":"4","key":"e_1_2_9_30_1","doi-asserted-by":"crossref","DOI":"10.3390\/cimb47040285","article-title":"The Expanding Role of GLP\u20101 Receptor Agonists: Advancing Clinical Outcomes in Metabolic and Mental Health","volume":"47","author":"Al Qassab M.","year":"2025","journal-title":"Current Issues in Molecular Biology"},{"issue":"4","key":"e_1_2_9_31_1","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s40501-024-00331-y","article-title":"The Impact of GLP\u20101 Receptor Agonists (GLP\u20101 RAs) on Mental Health: A Systematic Review","volume":"11","author":"Tempia Valenta S.","year":"2024","journal-title":"Current Treatment Options in Psychiatry"},{"issue":"9","key":"e_1_2_9_32_1","doi-asserted-by":"crossref","DOI":"10.3390\/life15091422","article-title":"GLP\u20101 Receptor Agonists in Mood Disorders: A Psychiatric Perspective","volume":"15","author":"Carmellini P.","year":"2025","journal-title":"Life"},{"key":"e_1_2_9_33_1","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.neuropharm.2017.11.015","article-title":"Glucagon\u2010Like Peptide\u20101 (GLP\u20101) and Neurotransmitters Signaling in Epilepsy: An Insight Review","volume":"136","author":"Koshal P.","year":"2018","journal-title":"Neuropharmacology"},{"key":"e_1_2_9_34_1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1148209","article-title":"Glucagon\u2010Like Peptide\u20101: A Multi\u2010Faceted Anti\u2010Inflammatory Agent","volume":"14","author":"Mehdi S. F.","year":"2023","journal-title":"Frontiers in Immunology"},{"issue":"2","key":"e_1_2_9_35_1","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00592-023-02184-y","article-title":"GLP\u20101RAs Inhibit the Activation of the NLRP3 Inflammasome Signaling Pathway to Regulate Mouse Renal Podocyte Pyroptosis","volume":"61","author":"Li X.","year":"2024","journal-title":"Acta Diabetologica"},{"issue":"9","key":"e_1_2_9_36_1","article-title":"Factors Associated With the Development of Depression and the Influence of Obesity on Depressive Disorders: A Narrative Review","volume":"12","author":"Alberti A.","year":"2024","journal-title":"Biomedicine"},{"key":"e_1_2_9_37_1","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2013.00177","article-title":"Metabolic Disturbances Connecting Obesity and Depression","volume":"7","author":"Hryhorczuk C.","year":"2013","journal-title":"Frontiers in Neuroscience"},{"issue":"3","key":"e_1_2_9_38_1","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.bodyim.2010.03.002","article-title":"Change in Body Image and Psychological Well\u2010Being During Behavioral Obesity Treatment: Associations With Weight Loss and Maintenance","volume":"7","author":"Palmeira A. L.","year":"2010","journal-title":"Body Image"},{"issue":"4","key":"e_1_2_9_39_1","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1017\/bec.2018.3","article-title":"The Relationship Between Body Image Concerns and Weight\u2010Related Behaviours of Adolescents and Emerging Adults: A Systematic Review","volume":"34","author":"Shagar P. S.","year":"2017","journal-title":"Behaviour Change"},{"key":"e_1_2_9_40_1","first-page":"149","article-title":"Weight Status and Body Image Perceptions in Adolescents: Current Perspectives","volume":"6","author":"Voelker D. K.","year":"2015","journal-title":"Adolescent Health, Medicine and Therapeutics"},{"key":"e_1_2_9_41_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.bodyim.2023.101678","article-title":"A Systematic Review of Weight Stigma and Disordered Eating Cognitions and Behaviors","volume":"48","author":"Levinson J. A.","year":"2024","journal-title":"Body Image"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00787\u2010021\u201001824\u20104"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2025.120160"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0328549"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pedn.2026.01.002"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc21\u20101995"},{"issue":"3","key":"e_1_2_9_47_1","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-040432","article-title":"Obesity in Childhood, Socioeconomic Status, and Completion of 12 or More School Years: A Prospective Cohort Study","volume":"11","author":"Lindberg L.","year":"2021","journal-title":"BMJ Open"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.71353","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dom.71353","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.71353","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T01:00:09Z","timestamp":1789434009000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/10.1111\/dom.71353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,14]]},"references-count":46,"alternative-id":["10.1111\/dom.71353"],"URL":"https:\/\/doi.org\/10.1111\/dom.71353","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,14]]},"assertion":[{"value":"2026-07-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"dom.71353"}}